US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816 [Hematologic Malignancy]
Conclusion
Response-adapted therapy based on interim PET imaging after two cycles of ABVD seems promising with a 2-year PFS of 64% for PET2-positive patients, which is much higher than the expected 2-year PFS of 15% to 30%.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Press, Li, Schoder, Straus, Moskowitz, LeBlanc, Rimsza, Bartlett, Evens, Mittra, LaCasce, Sweetenham, Barr, Fanale, Knopp, Noy, Hsi, Cook, Lechowicz, Gascoyne, Leonard, Kahl, Cheson, Fisher, Friedberg Tags: Clinical Trials, Risk factors, Diagnosis & Staging, Chemotherapy, Nuclear Medicine Hematologic Malignancy Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Hematology | HIV AIDS | Leukemia | Lymphoma | Nuclear Medicine | PET Scan | Prednisone | Toxicology